Novo Nordisk to submit interim data on Tresiba drug in U.S.

March 26 (Reuters) - Denmark's Novo Nordisk said on Thursday it had decided to submit interim analysis data from a clinical trial of its crucial new insulin drug Tresiba to U.S. regulators within the next month.